Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$30.5 million.

  • Stoke Therapeutics' Free Cash Flow fell 4042.73% to -$30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 16182.75%. This contributed to the annual value of -$87.1 million for FY2024, which is 528.65% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Free Cash Flow of -$30.5 million as of Q3 2025, which was down 4042.73% from -$25.6 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Free Cash Flow ranged from a high of $131.7 million in Q1 2025 and a low of -$30.5 million during Q3 2025
  • For the 4-year period, Stoke Therapeutics' Free Cash Flow averaged around -$8.7 million, with its median value being -$21.9 million (2023).
  • As far as peak fluctuations go, Stoke Therapeutics' Free Cash Flow plummeted by 16919.75% in 2023, and later surged by 63574.33% in 2025.
  • Stoke Therapeutics' Free Cash Flow (Quarter) stood at -$22.8 million in 2022, then rose by 8.36% to -$20.9 million in 2023, then decreased by 11.29% to -$23.2 million in 2024, then tumbled by 31.26% to -$30.5 million in 2025.
  • Its last three reported values are -$30.5 million in Q3 2025, -$25.6 million for Q2 2025, and $131.7 million during Q1 2025.